| Secondary |
| Product Used For Unknown Indication |
55.3% |
| Threatened Labour |
12.0% |
| Premature Labour |
8.0% |
| Asthma |
3.3% |
| Drug Exposure During Pregnancy |
3.3% |
| Neonatal Respiratory Distress Syndrome Prophylaxis |
2.7% |
| Calculus Ureteric |
2.0% |
| Infusion |
2.0% |
| Lactation Inhibition Therapy |
2.0% |
| Maternal Therapy To Enhance Foetal Lung Maturity |
2.0% |
| Pulmonary Tuberculosis |
2.0% |
| Anaesthesia |
1.3% |
| Influenza |
1.3% |
| Hypertension |
0.7% |
| Hypotonia |
0.7% |
| Muscle Relaxant Therapy |
0.7% |
| Tocolysis |
0.7% |
|
| Pulmonary Oedema |
17.9% |
| Premature Baby |
12.8% |
| Rhabdomyolysis |
12.8% |
| Abdominal Distension |
5.1% |
| Hypoxia |
5.1% |
| Live Birth |
5.1% |
| Neonatal Respiratory Distress Syndrome |
5.1% |
| Normal Newborn |
5.1% |
| Amniotic Fluid Volume Decreased |
2.6% |
| C-reactive Protein Increased |
2.6% |
| Hypoalbuminaemia |
2.6% |
| Maternal Drugs Affecting Foetus |
2.6% |
| Myocardial Infarction |
2.6% |
| Otocephaly |
2.6% |
| Potentiating Drug Interaction |
2.6% |
| Premature Delivery |
2.6% |
| Tachycardia |
2.6% |
| Tachycardia Foetal |
2.6% |
| Uterine Contractions Abnormal |
2.6% |
| Wound Dehiscence |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
12.7% |
| Schizophrenia |
7.4% |
| Infection |
7.0% |
| Tocolysis |
7.0% |
| Hiv Infection |
6.6% |
| Product Used For Unknown Indication |
5.7% |
| Vomiting |
5.2% |
| Autonomic Nervous System Imbalance |
4.8% |
| Personality Disorder |
4.4% |
| Antiviral Prophylaxis |
3.9% |
| Maternal Therapy To Enhance Foetal Lung Maturity |
3.9% |
| Threatened Labour |
3.9% |
| Bipolar Disorder |
3.5% |
| Drug Exposure During Pregnancy |
3.5% |
| Foetal Cardiac Disorder |
3.5% |
| Influenza |
3.5% |
| Myocarditis |
3.5% |
| Polyhydramnios |
3.5% |
| Vaginal Douching |
3.5% |
| Asthma |
3.1% |
|
| Premature Baby |
13.5% |
| Drug Exposure During Pregnancy |
10.4% |
| Somnolence Neonatal |
9.4% |
| Threatened Labour |
9.4% |
| Small For Dates Baby |
8.3% |
| Premature Labour |
6.3% |
| Trisomy 21 |
5.2% |
| Ventricular Tachycardia |
5.2% |
| Dystrophia Myotonica |
3.1% |
| Lung Disorder |
3.1% |
| Pleural Effusion |
3.1% |
| Premature Rupture Of Membranes |
3.1% |
| Renal Failure Acute |
3.1% |
| Tachycardia |
3.1% |
| Twin Pregnancy |
3.1% |
| Exposure During Pregnancy |
2.1% |
| Foetal Heart Rate Increased |
2.1% |
| Labour Complication |
2.1% |
| Live Birth |
2.1% |
| Neonatal Asphyxia |
2.1% |
|
| Interacting |
| Drug Exposure During Pregnancy |
20.8% |
| Maternal Exposure During Pregnancy |
20.8% |
| Ill-defined Disorder |
16.7% |
| Local Anaesthesia |
16.7% |
| Anxiety |
10.4% |
| Foetal Exposure During Pregnancy |
10.4% |
| Product Used For Unknown Indication |
4.2% |
|
| Tachycardia |
40.0% |
| Foetal Heart Rate Abnormal |
30.0% |
| Apgar Score Low |
10.0% |
| Drug Interaction |
10.0% |
| Injection Site Pain |
10.0% |
|
